1205189446

1205189446 was paid $2.19M by Medicaid between Jan 2018 and Apr 2024, across 33 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 26% of everything it billed.

33Billing provider info1205189446

33aNPI1205189446

33bProvider type—

28Total paid$2.19M

24GClaims50,357

24DCodes billed33

24AFirst – last monthJan 2018 – Apr 2024

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	12,688	$780K
2019	11,918	$509K
2020	7,399	$279K
2021	6,497	$237K
2022	5,906	$193K
2023	4,765	$158K
2024incomplete	1,184	$36K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	26%	4,001	3,251	$562K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	25%	12,695	11,185	$538K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	20%	18,714	16,132	$439K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	12%	3,646	3,376	$260K
99490	Ccm add 20min	4.2%	4,576	4,413	$93K
62323		3.3%	621	514	$73K
99203	Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity	2.8%	1,110	988	$62K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	2.5%	440	409	$54K
J0702	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg	1.2%	1,452	1,201	$26K
99439		<1%	681	662	$15K
77002		<1%	359	260	$10K
J3300	Injection, triamcinolone acetonide, preservative free, 1 mg	<1%	48	44	$9K

21 more codes

20610		<1%	197	$6K
64493		<1%	80	$6K
99204	Doctor's office visit, new patient (more involved)	<1%	45	$3K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	495	$3K
64635		<1%	12	$3K
64494		<1%	70	$3K
64495		<1%	71	$3K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	89	$3K
82670		<1%	89	$2K
62321		<1%	16	$2K
64636		<1%	12	$2K
84403		<1%	89	$2K
82626		<1%	89	$2K
84270		<1%	89	$2K
84144		<1%	89	$2K
83001		<1%	89	$2K
83002		<1%	89	$2K
82533		<1%	89	$1K
82607		<1%	89	$1K
99491	Ccm add 20min	<1%	27	$1K
G0506	Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service)	<1%	99	$176.22

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.